Evidence map›Paper›PMID 42898812›Full record

ArticleClinical kidney journal2026

Kidney involvement in idiopathic multicentric Castleman disease-TAFRO syndrome: clinical spectrum, pathology and outcomes.

Shuo Zhang, Hanshu Liu, Siyuan Li, Yubing Wen, Wenling Ye, Wei Ye, Hua Zheng, Lubin Xu, Fei Teng, Ying Wang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shuo ZhangDepartment of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China.ORCID https://orcid.org/0000-0001-8171-2779
Hanshu LiuDepartment of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China.
Siyuan LiDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing,China.
Yubing WenDepartment of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China.
Wenling YeDepartment of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China.
Wei YeDepartment of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China.
Hua ZhengDepartment of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China.
Lubin XuDepartment of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China.
Fei TengDepartment of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China.ORCID https://orcid.org/0000-0002-8834-5067
Ying WangDepartment of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China.
Ke ZhengDepartment of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China.
Peng XiaDepartment of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China.
Lu ZhangDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing,China.
Jian LiDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing,China.ORCID https://orcid.org/0000-0002-4549-0694
Xuemei LiDepartment of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China.
Limeng ChenDepartment of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China.ORCID https://orcid.org/0000-0002-8425-5742

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Idiopathic multicentric Castleman disease-thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly syndrome (iMCD-TAFRO) is a clinically aggressive subtype. Renal involvement and its impact on prognosis are poorly characterized. We aimed to describe renal clinicopathological features and outcomes in a large iMCD-TAFRO cohort. Methods: This 10-year retrospective cohort study enrolled iMCD-TAFRO patients at Peking Union Medical College Hospital. Renal involvement was defined by iMCD consensus criteria. Survival was analyzed using Kaplan-Meier methods. Results: A total of 48 patients (70.8% male; mean age 45 ± 15 years) were included. Renal involvement was observed in 95.8% (46/48) of the patients, presenting predominantly with reduced urine output, mild hematuria and proteinuria, as well as elevated serum creatinine. Acute kidney injury (AKI) occurred in 80.4% (37/46) of patients showing renal involvement and 37.8% of them required renal replacement therapy. Renal biopsies ( Conclusions: Renal involvement in iMCD-TAFRO is common and frequently manifests as AKI associated with systemic inflammation. Early and aggressive therapy combined with supportive renal care, including timely dialysis, improved renal recovery and overall prognosis.

Indexed as

dialysisidiopathic multicentric Castleman diseaseprognosisrenal injuryTAFRO subtype

Identifiers

PMID42898812
PMCPMC13678736

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.